NCT06595784 The HELlenic Thoracic Society Initiative for CΟPD and CVD
| NCT ID | NCT06595784 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hellenic Thoracic Society |
| Condition | Chronic Obstructive Pulmonary Disease (COPD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 900 participants |
| Start Date | 2024-10-15 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 900 participants in total. It began in 2024-10-15 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
COPD is one of the most common respiratory diseases in Greece, and maybe more than half a million Greek citizens suffer both from COPD and CVD, however their characteristics and management remain unknown. HELICOPD is a national, multicenter, prospective, non-interventional study designed to contribute to better understanding and depicting the demographic and clinical characteristics of this population, the COPD- and CVD-related adverse events in a two-years period, their quality of life and the healthcare resources use. The study is initiated and coordinated by the Hellenic Thoracic Society.
Eligibility Criteria
Inclusion criteria Patients should cumulatively meet the following three (3) criteria to be enrolled in the study: 1. To have been diagnosed with chronic obstructive pulmonary disease and at least one cardiovascular comorbidity (heart failure, atherosclerotic cardiovascular disease, atrial Fibrillation, severe valvular disease) 2. Adults aged \>35 years at the time of inclusion in the study, 3. With signed informed consent for their participation in the study. Exclusion criteria Patients with the below limitations are not eligible to participate in the study Patients: 1. Without at least one cardiovascular comorbidity, 2. With history of lung cancer 3. With any other active malignancy and undergoing treatment (chemotherapy/radiotherapy/immunotherapy) 4. With any thoracic or abdominal surgery planned during study follow-up period 5. With participation in any COPD-related interventional study at study entry or during study duration. 6. Without signed informed consent for their participation in the study.
Contact & Investigator
Georgios Hillas
PRINCIPAL INVESTIGATOR
5th Pulmonary Department, "Sotiria" Chest Diseases Hospital, Athens, Greece
Frequently Asked Questions
Who can join the NCT06595784 clinical trial?
This trial is open to participants of all sexes, aged 35 Years or older, up to 99 Years, studying Chronic Obstructive Pulmonary Disease (COPD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06595784 currently recruiting?
Yes, NCT06595784 is actively recruiting participants. Contact the research team at loukstel@med.uoa.gr for enrollment information.
Where is the NCT06595784 trial being conducted?
This trial is being conducted at Alexandroupoli, Greece, Athens, Greece.
Who is sponsoring the NCT06595784 clinical trial?
NCT06595784 is sponsored by Hellenic Thoracic Society. The principal investigator is Georgios Hillas at 5th Pulmonary Department, "Sotiria" Chest Diseases Hospital, Athens, Greece. The trial plans to enroll 900 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.